Listed by the USPTO as SKOKO III, JOHN JOSEPH
Tech Center 1600 • Art Units: 1612 1641 1643 1644
This examiner grants 53% of resolved cases
SKOKO III, JOHN JOSEPH works in Tech Center 1600 and art unit 1612. The profile reports 115 resolved cases and an allowance rate of 53.0%. The interview lift is 55.2%, slightly above the allowance rate, making interview preparation a meaningful part of prosecution planning. The median time to allowance is 1344 days, so applicants should account for extended examination when setting portfolio expectations.
The listed companies are Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Sapreme Technologies B V, and R.P. Scherer Technologies LLC. The listed firms are FOLEY & LARDNER LLP, Ipsilon USA - NLO, and Jones Day. The smaller resolved-case base supports measured interpretation, while the available data favors clear interview objectives and well-supported alternative claim positions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18912748 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17338569 | COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY | Non-Final OA | Hoffmann-La Roche Inc. |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Non-Final OA | Novartis AG |
| 17595671 | COMBINATION THERAPY | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18284800 | COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA | Final Rejection | Juno Therapeutics, Inc. |
| 18463903 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | Non-Final OA | Ajinomoto Co., Inc. |
| 17431270 | USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES, AND EXOSOMES TO ASSAY IMMUNE CELL POTENCY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18524157 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Non-Final OA | Synthorx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy53.0% of resolved applications examined by John Joseph Skoko III were allowed (115 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.
This examiner's interview lift is +55.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by John Joseph Skoko III took 1,344 days on average from filing to allowance.
John Joseph Skoko III examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
